Larger effects seen for people from lower-income households.
As primary care clinicians are on the front lines of care for patients with COPD, they should educate them on the disease process, medication regimens, and nonpharmacologic treatments.
Prevalence of COPD higher in southeastern and Appalachian states, regardless of smoking status.
Substantial contribution seen to burden of diseases including asthma, COPD, chronic bronchitis, fibrosis.
Women are more likely to be symptomatic, have greater odds of frequent, severe acute exacerbations.
Individuals with HDHP more likely to report forgoing care due to costs, cost-related nonadherence.
Ginseng is nonsuperior to placebo for improving health-related quality of life in patients with stable symptomatic COPD.
The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the US FDA.
The duration of antibiotic regimens to treat lower respiratory tract infection can be reduced through the use of a procalcitonin-guided algorithm.
Review shows supplementation only effective for baseline vitamin D levels 25 nmol/L.
Cognitive behavioral therapy delivered by respiratory nurses is associated with reduced anxiety symptoms and is cost-effective for patients with chronic obstructive pulmonary disease
Strong dose-response relationship seen in never-smokers aged 50 and older.
Elderly, those living 10 miles from facility, those with lower SES less likely to receive pulmonary rehab.
The most common error related to the use of metered dose inhalers was the failure to attach the inhaler to a spacer.
For patients with chronic obstructive pulmonary disease and comorbid posttraumatic stress disorder, long-term benzodiazepine use is not associated with mortality, but there is an association for short-term benzodiazepine use.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
Serologically assessed collagen remodeling plays a key role in the severity of COPD, as determined by airflow limitation and dyspnea, as well as in disease outcomes.
The use of formal palliative care services among patients with chronic obstructive pulmonary disease increased by 1% per year, going from 5.3% in 2004 to 14.3% in 2014.
A 55-year-old man with chronic obstructive pulmonary disease reports having some mild chest pain.
Researchers examined real-world characteristics of patients receiving albuterol multidose dry powder inhaler or short-acting β2 agonists with short-acting β2 agonists for asthma and chronic obstructive pulmonary disease.